BioCardia, Inc. and StemCardia, Inc. announced a long-term partnership to advance StemCardia?s investigational pluripotent stem cell product candidate for the treatment of heart failure. Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia?s cell therapy candidate through studies expected to result in FDA approval of an investigational new drug application (IND) and the anticipated Phase I/II clinical development to follow.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4 USD | +1.52% | +6.67% | -39.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.78% | 10.59M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- BCDA Stock
- News BioCardia, Inc.
- BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure